Search Clinical Trials in the European Union

≤3 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
41-60 of 240 trials

Advanced Non-Small Cell Lung Cancer: OSIBOOST 2 Study

We are testing a modified dosing strategy of osimertinib, with or without a booster drug, for patients with advanced EGFR mutated NSCLC. This study aims to improve treatment cost-effectiveness and reduce side effects while maintaining effectiveness.

Non-Small Cell Lung Cancer with an EGFR Mutation≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncologyPulmonology

Prostate Cancer: Abiraterone and Oxycodone Study

We are investigating how abiraterone affects the metabolism of oxycodone in men with prostate cancer. This may help improve pain management for patients using these medications.

Prostate Cancer≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesInternal MedicineOncologyUrology

End-Stage Renal Disease: Rivaroxaban Dosing Study

We are studying different doses of rivaroxaban to find the safest option for patients on chronic hemodialysis. The trial will also look at the risk of bleeding with each dose.

Chronic Hemodialysis≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNephrology

Tumor Treatment: Botensilimab and Balstilimab Study

We are studying a new combination of immune therapies for patients with specific tumor types to see if it can reduce tumor size before surgery. This trial aims to improve treatment effectiveness and safety.

dMMR Tumors≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Juvenile Idiopathic Arthritis: Filgotinib Study

We are studying how the medication filgotinib works in children and teens with juvenile idiopathic arthritis. The trial will also evaluate its safety and how well young patients accept the medication.

Juvenile Idiopathic Arthritis≤3 monthsSafety phase (I)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPediatricsRheumatology

Acute Myeloid Leukemia: DASATINIB Treatment Study

We are evaluating the effectiveness of DASATINIB for patients with acute myeloid leukemia who did not respond to previous treatments. The study aims to see if this medication can help reduce tumors and identify factors that predict response.

Acute Myeloid Leukemia≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Lung Cancer: Enhanced Skin Care Management

We are studying if improved skin care can help reduce skin side effects in patients with advanced EGFR-mutated lung cancer receiving amivantamab and lazertinib. This trial compares enhanced care to standard skin management.

EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer≤3 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteDermatologyOncology

Sepsis-Associated Acute Kidney Injury: TIN816 Treatment Study

We are investigating a new treatment, TIN816, for individuals with sepsis-related kidney injury. The study aims to see if it improves kidney function and overall health compared to a placebo.

Sepsis-Related Acute Kidney Injury≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteInternal MedicineNephrology

Basal Cell Carcinoma: Tirbanibulin (Klisyri®) Treatment Study

We are studying the effectiveness and safety of Tirbanibulin (Klisyri®) for treating superficial basal cell carcinoma. The trial will also look at how well patients tolerate the treatment and their overall satisfaction.

Superficial Basal Cell Carcinoma≤3 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesDermatology

Severe Community-Acquired Pneumonia: AON-D21 Treatment Study

We are testing a new drug, AON-D21, as an additional treatment for patients with severe community-acquired pneumonia in intensive care. The study aims to assess its safety and effectiveness compared to a placebo.

Severe Community-Acquired Pneumonia≤3 monthsEfficacy phase (II)>20 visitsInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Hypertonic Lactate After Cardiac Arrest: The LATTE Trial

We are studying whether hypertonic sodium lactate can help reduce brain injury in comatose survivors of cardiac arrest. This trial will also look at its effects on recovery and safety.

Cardiac ArrestComaPost Cardiac Arrest Syndrome≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyNeurology

Cerebral Amyloid Angiopathy: New Treatment Approaches

We are studying whether non-invasive vagus nerve stimulation and low-sodium oxybate can help clear amyloid-beta from the brain in patients with cerebral amyloid angiopathy. This research aims to improve understanding of potential treatments for this condition.

Cerebral Amyloid Angiopathy≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Menopausal Women with Breast Cancer: Prasterone Therapy

We are studying whether a vaginal treatment can improve urinary and vaginal symptoms in menopausal women with a history of breast cancer or those currently on hormone therapy. The goal is to see how this therapy affects their quality of life and overall wellbeing.

Breast CancerGenitourinary Syndrome of Menopause≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncologyUrology

Advanced Solid Tumors: Testing IPN01194

We are studying a new drug, IPN01194, for adults with advanced solid tumors to see how safe it is and how well it works. This trial aims to understand its effects when used alone.

MelanomaPancreatic Ductal AdenocarcinomaColorectal Cancer≤3 monthsSafety phase (I)Efficacy phase (II)No PlaceboCost ReimbursementOncology

Suicidal Thoughts: Nitrous Oxide Treatment in Emergencies

We are studying whether inhaling a mix of nitrous oxide and oxygen can reduce suicidal thoughts in patients at emergency departments. The trial also looks at its effects on anxiety and depression symptoms over time.

Suicidal Thoughts≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPsychiatry

Major Depressive Disorder: NMRA-335140 Study

We are testing a new oral medication for adults with major depressive disorder to see if it helps improve their symptoms compared to a placebo. The study will measure changes in mood and daily functioning over six weeks.

Major Depressive Disorder≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Chronic Kidney Disease: FINESSE Study on Albuminuria Reduction

We are researching how well finerenone and semaglutide can lower albuminuria in patients with chronic kidney disease. The goal is to find the most effective treatment for each individual and explore remote monitoring options.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyNephrology

Liver Transplant: Low-Dose Arginine-Vasopressin Study

We are investigating whether low-dose arginine-vasopressin can reduce kidney injury after liver transplantation. This study aims to improve recovery and outcomes for transplant patients.

Acute Kidney InjuryLiver Transplantation≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesHepatologyNephrology

Early Rectal Cancer: FARE Trial with [68Ga]Ga-FAPI-46 PET/CT

We are studying a new imaging method to detect lymph node spread in early rectal cancer patients. This trial aims to see if it provides more accurate results than standard imaging techniques.

Rectal Cancer≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInfectious DiseasesInternal MedicineOtolaryngology

Schizophrenia: Intensified Treatment Study

We are investigating whether a six-week intensified medication plan helps individuals with schizophrenia who didn't respond to their first treatment. The study looks at changes in symptoms, functioning, and overall well-being compared to standard care.

Schizophrenia and Related Disorders≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePsychiatry